Thyroid cancers

Azra Tabassum

Introduction

- **EPIDEMIOLOGY:**
- 3% to 7% palpation
- •Palpable thyroid nodules 5% in women and 1% in men
- Male have higher risk of cancer
- Single nodule is more likely malignant than multiple nodules
- Nodules in children and the elderly have a higher risk of malignancy
- •Differentiated thyroid cancer comprises 90% of all thyroid cancers
- •2.4 fold increase in yearly incidence of thyroid cancer
- •49% of rising incidence consisted of cancers <1cm
- •87% of rising incidence consisted of cancers <2cm

Thyroid cancers

Pathological classification

1-Well differentiated malignant neoplasm

(85% of thyroid cancer)

- Papillary thyroid malignant neoplasm(PTC)85%
- Follicular thyroid carcinoma (FTC) -10%
- Hurthle cell carcinoma (HCC) 3%

2--Poor differentiated malignant neoplasm

- Medullary Thyroid carcinoma (MTC) 3%
- Anaplastic thyroid carcinoma (ATC)
- Insular thyroid carcinoma (ITC)

3– Other malignant tumours

- Lymphoma
- Metastatic tumours

Thyroid cancers

Primary :

1- Follicular epithelium –well differentiated

papillary

Follicular

2- Follicular Epithelium –undifferentiated

Anlaplastic

3- Parafollicular cells

Medullary

4- Lymphoid cells

Lymphoma

Secondary:

metastatic

Risk factors

Radiation :
High dose -x ray exposure to thyroid gland

Family history :
a 4 to 10 fold increased risk of well differentiated thyroid cancer in 1st degree relatives

Gender :
female

Iodine levels :
iodine deficient diets may lead to increase the TSH levels and considered goitorgenic

Thyroiditis (Hashimoto's disease) :
may develop into a form of cancer called Lymphoma

Evaluation of thyroid cancers

History :
Age and gender
Rapid increase in size , dyspnoea, dysphagia and hoarseness of voice

Family history : history of thyroid cancers
Personnel history of irradiation

On Examination:
Firmness, mobility, size and adherence to surrounding structure
Presence of lymphadenopathy

Thyroid function test and imaging

Blood test :

- T_4, T_3, TSH (thyroid function tests)
- Ca , PTH (hyperparathyroidism assoc. With TC)
- TG (increase in recurrent --WDTC)
- Calcitonin (incrase in MTC)

Recommendation :

- Measure serum TSH in initial evaluation of patient with a thyroid nodule.
- If serum TSH is subnormal, a radionuclide thyroid scan should be performed with technetium 99mTc pertechnetateor 123 I

- Thyroid US should be performed in all patients with known or suspected thyroid nodules
- Routine assessment of serum thyroglobulin for initial evaluation of thyroid nodules is not recommended
- Equivocal recommendation for routine assessment of serum calcitonin

Imaging –US

Sensitive 80%
Detect nodule 2-3 mm
Differentiation between cystic and solid lesion
F/U cystic asp , re collection of fluid
Valuable tool for collection of Biopsy (FNA)

Higher likelihood of malignancy

- Nodule hypoechogenicity
- Increased intranodularvascularity
- Irregular infiltrative margins
- Microcalcifications
- Absent halo
- Extra glandular extension
- Shape taller than width measured in transverse dimension

Imaging -US

PAPILLARY THYROID CANCER

- Solid and hypoechoic
- Infiltrative irregular margins
- Increased nodular vascularity
- Microcalcifications



FOLLICULAR THYROID CANCER

- Iso-to hyperechoic
- Thick and irregular halo
- No microcalcifications



Imaging –US findings

Abnormal metastatic lymph nodes

- Loss of fatty hilus
- Rounded rather than oval shape
- Hypoechogenicity
- Cystic change
- Calcifications
- Peripheral vascularity



Diagnosis -FNA

Fine needle aspiration(FNA):

Advantages:

Procedure of choice in the evaluation of thyroid nodules

Easy to perform. Less morbidity

Most accurate and cost effective method

• **US guided FNA preferred** : Decrease the incident of non diagnostic specimen , increase the sensitivity and specificity

Avoiding vascular structure

Accuracy from FNA ranges from 70% to 97% and highly depended on the skill of the physician and the cytopathologist interpreting it

Disadvantage:

Less tissue for diagnosis

Limit in differentiation of certain types of thyroid Cancer

Follicular adenoma vs carcinoma

Hurthel cell adenoma vs Carcinoma

Diagnosis-FNA



Diagnosis –Core needle biopsy

Core needle biopsy:

Advantages :

-Adequate tissue for diagnosis

Disadvantages

- more difficult
- more traumatic
- more complication

Role of FNA

US guidance for FNA is recommended for nodules that are

- Nonpalpable
- Predominantly cystic
- Posterior location in thyroid

Cytology results

- Nondiagnostic cytology
- Malignant Cytology
- Indererminate cytology

Nondiagnostic cytology

FNA cytology

Nondiagnostic cytology (>25-50% cystic component)

- Sampling error (difficult to palpate or posteriorly located nodules)
- Palpation or US guided FNA possible

•If FNA --Fail to meet specified criteria for cytologicadequacy that have been previously established

Recommendation:

- US guidance should be used when repeating the FNA procedure for a nodule with an initial nondiagnostic cytology result
- Partially cystic nodules that repeatedly yield non diagnostic aspirates need close observation or surgical excision with strong consideration if the cytologically nondiagnostic nodule is solid

Malignant Cytology

FNA cytology

If diagnostic US confirms predominantly solid nodule corresponding to palpation - FNA Biopsy Results

- Nondiagnostic
- Malignant
- Indeterminate / Suspicious for Neoplasm
- Benign

If malignant Cytology

Recommendation :

- If a cytology result is diagnostic of or highly suspicious for PTC, surgery is recommended.

Indeterminate Cytology

FNA cytology

Indeterminate Cytology

- **Follicular neoplasm / Hurthle cell neoplasm**

  20-30% risk of malignancy

- **Atypia/ Follicular lesion of undetermined significance**

  5-10% risk of malignancy

  Overall predictive values low

- **Improved preoperative diagnostic accuracy with**

  Genetic markers -BRAF, Ras, RET/PTC

  Protein markers -Galectin-3

Indeterminate Cytology

FNA cytology

Indeterminate cytology
Recommendations:

- Molecular markers may be considered to help guide management

- Equivocal for routine use of 18FDG-PET scan to improve diagnostic accuracy of indeterminate thyroid nodule

- If follicular neoplasm reported, consider a 123I thyroid scan especially with low-normal serum TSH. If a concordant autonomously functioning nodule is not seen, consider lobectomy or total thyroidectomy

- If "suspicious for papillary carcinoma" or "Hurthlecell neoplasm" reported, 123I scan is not needed, lobectomy or total thyroidectomy is recommended depending on lesions size.

BENIGN CYTOLOGY

FNA cytology

Benign Cytology

Recommendation :

- If the nodule is benign on cytology, further immediate diagnostic studies or treatment are not routinely required

The Bethesda System for Reporting Thyroid Cytopathology

: Recommended Diagnostic Categories*

I. **Nondiagnostic or Unsatisfactory Cyst fluid** only Virtually acellular specimen Other (obscuring blood, clotting artifact, etc)

II. II. **Benign Consistent with a benign follicular nodule** (includes adenomatoid nodule, colloid nodule, etc) Consistent with lymphocytic (Hashimoto) thyroiditis in the proper clinical context Consistent with granulomatous (subacute) thyroiditis Other

III. III. **Atypia of Undetermined Significance** or Follicular Lesion of Undetermined Significance

IV. IV. **Follicular Neoplasm or Suspicious for a Follicular Neoplasm** Specify if Hürthle cell (oncocytic) type V. Suspicious for Malignancy Suspicious for papillary carcinoma Suspicious for medullary carcinoma Suspicious for metastatic carcinoma Suspicious for lymphoma Other

V. VI. **Malignant Papillary thyroid carcinoma** Poorly differentiated carcinoma Medullary thyroid carcinoma Undifferentiated (anaplastic) carcinoma Squamous cell carcinoma Carcinoma with mixed features (specify) Metastatic carcinoma Non-Hodgkin lymphoma

Diagnosis –thyroid scan

Radionuclide scan:

- To determine the functional status of the nodule
- Distinguish functioning toxic nodules and metastasis from PTC and FTC

Hypo functional " cold nodule" –16% contain tumour
Hyper functioning " hot nodules" – 4% contain tumour
Normal uptake "warm nodules"

(Radioactive iodine or technetium uptake)

- **Gallium scan** -- is used in the diagnosis of thyroid lymphoma

- Uses today
  - indeterminate FNA
  - Large benign nodules (> 4cm)

Diagnostic imaging

CT:

- Detect tracheal invasion
- Evaluate for cervical nets

MRI:

- Useful to detect for residual, reccuent and metastasises carcinoma
- T2 differentiate between tumour and fibrosis

Chest Xray :

Tracheal deviation , airway narrowing , lung metastasis

Papillary Thyroid Carcinoma (PTC)

- Most common WDTC - 75%-85%
- 80%-90% of radiation-induced TC
- Peak incidence: 30s-40s
- 10 year-survival: 84%-90%
- Female: male ratio is 3:1
- cystic or solid
- Spread through lymphatic

Clinical presentation :

- **Incidenta**l : As a small occult tumour < 1 cm Papillary microcarcinoma)
- **Mass in the neck** -The commonest way papillary cancer present
- **Distant spread**: Spread to lung or bone is very rare but when it occurs unlike other cancers , cure

PTC – pathology Variants

Microcarcinoma
Macrocarcinoma
Encapsulated
Follicular
Oncocytic
Solid

Diffuse Follicular
Diffuse Sclerosing
Tall Cell
Columnar
Dedifferentiated

- Gross – Non-encapsulated – Central necrosis with fibrosis or haemorrhage – Cystic degeneration in large tumours

- Multicentricity in 75% of tumours – High rate of metastasis to regional lymph nodes (50%)



PTC - pathology



- Histology
  - Papillary projections
  - Nuclei
    - Vesicular and ground-glass “Orphan Annie” appearance
    - High N:C ratio
    - Mitotic figures

Follicular thyroid carcinoma (FTC)

- Peak in 50s
- Female to male ratio 3:1
- 10 yrs survival rate : 86% in non invasive tumours , 44% in invasive tumour

Spread by the blood stream and rarely through lymphatic

Clinical presentation:

- As a single ,ump in the thyroid -- the commonest presentation
- As pain in a bone or a spontaneous fracture: In case of metastasis to bone through the blood streams

•It is unifocal, thickly .
•well encapsulated
•Cystic degeneration
• Calcification
• Haemorrhage
•Tendency to invade the thyroid capsule and blood vessels

• and shows invasion of both capsule and blood vessels

PTC vs FTC

	Papillary (%)	Follicular (%)
Male incidence	22	35
Lymph node metastases	35	13
Blood vessel invasion	40	60
Recurrence rate	19	29
Overall mortality rate	11	24
Location of recurrent carcinoma		
Distant metastases	45	75
Nodal metastases	34	12
Local recurrence	20	12

Hurthle Cell Carcinoma (HCC)

- Most aggressive type of WDTC
- About 5% of WDTC !
- High incidence of bilateral thyroid lobe involvement
- High incidence of recurrence and high mortality

Differentiated thyroid cancer

GOALS OF THERAPY

- **Remove primary tumour, disease that has extended beyond thyroid capsule and involved cervical lymph nodes.**
- **Residual metastatic lymph nodes represent the most common site of recurrence**

Minimize treatment related morbidity
Accurate staging
Facilitation of postoperative radioiodine treatment

- **Accurate long term surveillance for disease recurrence**

Minimize recurrence and metastasis

Lymph node involvement

Malignant nodes more likely in levels III, IV, VI



FIG. 2. Lymph node compartments separated into levels and sublevels. Level VI contains the thyroid gland, and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the innominate (brachiocephalic) artery, and laterally on each side by the carotid sheaths. The level II, III, and IV nodes are arrayed along the jugular veins on each side, bordered anteromedially by level VI and laterally by the posterior border of the sternocleidomastoid muscle. The level III nodes are bounded superiorly by the level of the hyoid bone, and inferiorly by the cricoid cartilage; levels II and IV are above and below level III, respectively. The level I node compartment includes the submental and submandibular nodes, above the hyoid bone, and anterior to the posterior edge of the submandibular gland. Finally, the level V nodes are in the posterior triangle, lateral to the lateral edge of the sternocleidomastoid muscle. Levels I, II, and V can be further subdivided as noted in the figure. The inferior extent of level VI is defined as the suprasternal notch. Many authors also include the pretracheal and paratracheal superior mediastinal lymph nodes above the level of the innominate artery (sometimes referred to as level VII) in central neck dissection (166).

Differentiated thyroid cancer

Recommendation - Imaging

• Preoperative neck US for contralateral lobe and cervical lymph nodes –central and lateral neck compartments –is recommended for all patients undergoing thyroidectomy for malignant cytologicbiopsy findings.

• US guided FNA of sonographically suspicious lymph nodes should be performed to confirm malignancy

Laboratory Tests:

• Routine preoperative serum Tg measurement is not recommended

Surgical option

Surgical options to address the primary tumour include

- **Hemithyroidectomy with or without isthmusectomy**

  Near total thyroidectomy

- **Removal of all grossly visible thyroid tissue, leaving only a small amout <1g of tissue adjacent to the recurrent laryngeal nerve near the ligament of Berry**

  Total thyroidectomy

  Removal of all grossly visible thyroid tissue

  Subtotal thyroidectomy

- **Leaving >1g of tissue with the posterior capsule on the uninvolved side**

  Inappropriate operation for thyroid cancer

Surgery for non diagnostic biopsy

RECOMMENDATIONS

• Isolated indeterminate solitary nodule who prefer a more limited surgical procedure, thyroid lobectomy is recommended initial surgical approach

• Due to an increased risk of malignancy, total thyroidectomy is indicated in patients with indeterminate nodules with large tumours >4cm, when biopsy contains marked atypia or is suspicious for papillary carcinoma, and in patients with a history of radiation exposure and a family history of thyroid cancer

• Patients with indeterminate nodules with bilateral nodular disease should undergo total or near total thyroidectomy

Surgery for malignant biopsy

RECOMMENDATIONS

- For patients with thyroid cancer >1cm, initial surgical procedure should be a near-total or total thyroidectomy

- For small <1cm, low risk, unifocal, intrathyroidal papillary carcinomas in the absence of prior head and neck irradiation or radiologically or clinically involved cervical nodal metastases, thyroid lobectomy alone may be sufficient

Lymph node dissection

Recommendation:

- Therapeutic central compartment (level VI) neck dissection for patients with clinically involved central or lateral neck lymph nodes should accompany total thyroidectomy to provide clearance of disease from the central neck

- Prophylactic central compartment neck dissection (ipsilateralor bilateral) may be performed in patients with papillary thyroid cancer with clinically uninvolved central neck lymph nodes, especially for advanced primary tumours (T3/T4)

- Near total or total thyroidectomy without prophylactic central neck dissection may be appropriate for small (T1/T2), non invasive, clinically node negative PTCs and most follicular cancers

Medullary thyroid cancer

- Calcitonin producing tumour of Parafollicular cells
- 3% of thyroid cancers, third most common thyroid cancer
- Overall 5 year survival rate 80-86%,10-year survival rate 75%
- 5 year survival rate 100% stage I, 98% stage II, 81% stage III, 28% stage Ivin

Clinical presentation:

- Symptoms –flushing, diarrhoea, pruritus
- Signs –thyroid nodule, cervical lymphadenopathy
- Increased calcitonin

- Poorer prognosis than that differentiated thyroid cancer post metastasis beyond thyroid gland
- Surgery and radiation therapy

Medullary thyroid cancer

Types of MTC :
Familial MTC & Sporadic MTC

• 25% of medullary thyroid cancer is genetic in nature, caused by a mutation in the RET proto-oncogene, termed *familial MTC*

• When MTC occurs alone, termed *sporadic MTC*

•When coexists with parathyroid gland tumours and medullary component of the adrenal glands (pheochromocytoma), termed *multiple endocrine neoplasia type 2 (MEN2)*

FAMILIAL SYNDROMES PREDISPOSING TO THYROID CANCER
ϒMEN2
ϒFamilial adenomatous polyposis
ϒCowden syndrome
ϒCarney complex
ϒ**Pendredsyndrome**
ϒWerner syndrome

Anaplstic thyroid cancer

- It is very aggressive tumour with a poor prognosis
- Always presents as stage IV
- Overall 5 year survival rate 7%
- Female to male ratio of 1,5:1

Commonest in areas of endemic goitre where there is chronic iodine deficiency

Clinical feature :

- A long standing goitre that suddenly increase in size
- Local invasion lead to obstructive symptoms haemoptysis', dysphagia and hoarsness
- At the time of the diagnosis 25 to 50 % of pat have synchronous pulmonary metases

- Treatment palliative in intent
- Radiation therapy combined with chemotherapy

Thyroid lymphoma

AImost is relatively rare disease -- <1% of all lymphoma and accounting for 2% of extra nodal non Hodgkin's lymphoma
Female to male ratio is 3:1 to 8:1
Median age is seventh decade of life

Clinical presentation :
Local invasion: hoarsness, dysphonia with strider or dysphagia
Hypothyroidism in case of auto immune thyroiditis or Hashimoto's thyroiditis

The prognosis in differentiated thyroid carcinoma

	Low risk	High risk
Patient age	< 45 y	> 45 y
Tumor size	< 4.0 cm	> 4.0 cm
Extrathyoidal extension	absent	present
Distant metastases	absent	present
High tumor grade	absent	present

Prognostic factors

RECURRENCE RISK

Low risk:

- No local or distant metastases
- Complete resection of all macroscopic tumour
- No locoregional invasion
- No aggressive histology or vascular invasion
- If I131 is given, no I131 uptake outside thyroid bed on the 1st post treatment whole body RAI scan

Prognostic factors

RECURRENCE RISK

• **Intermediate Risk**

Any of the following
• Microscopic tumour invasion into perithyroidal soft tissues at initial surgery
• Cervical lymph node metastases
• 131I uptake outside thyroid bed on whole body RAI scan done after thyroid remnant ablation
• Tumour with aggressive histology or vascular invasion

Prognostic factors

RECURRENCE RISK

High risk

- Macroscopic tumour invasion
- Incomplete tumour resection
- Distant metastases
- Thyroglobulinaemia out of proportion to post treatment scan

Treatment option

Consist of a three pronged attack

- Thyroid surgery
- Radioactive iodine treatment
- Drug –thyroxin therapy

Radioiodine therapy

Recommendation:

- Patent with Stage 111 or 1V Disease
- All pat with stage 11 disease
- Selected pat with stage 1 disease those with
  Large tumour (1,5cm)
  Multifocal tumour
  Residual disease
  Nodal metastasis

C cell don't concentrate iodine so is of no value in the management of MTC

Thyroxin Therapy

Evidence supported efficacy of TSH suppression in preventing adverse clinical effect

High risk patient: are maintained at TSH level below 0.1 mu/L

Low risk patient : TSH level at or below the normal range (0.1 -0.5 mu/L)

Medullary thyroid cancer

Surgery is the only definitve treatment
(Total thyroidecotomy, central node dissection and ispiliateral modified radical neck dissection

Familial MTC
Based on the genetic test for the mutation of RET gene
MEN 2a :prophylactic therapy at the age of 5 to 6 yrs
MEN2b: Thyroidectomy during infancy

Anaplastic Thyroid Cancer

- In the majority of cases surgery is limited to an open biopsy to exclude Lymphoma
- External beam radiotherapy as been used with limited success to treat locally recurrent ATC

- Doxorubicin is the single most effective chemotherapeutic agent for ATC

Long term management

CRITERIA FOR ABSENCE OF PERSISTENT TUMOUR

In patients who have undergone total or near total thyroidectomy and remnant ablation, disease free status comprises

No clinical evidence of tumour
No imaging evidence of tumour

•Undetectable serum Tg levels during TSH suppression and stimulation in absence of interfering antibodies

Long term follow up

RECOMMENDATIONS FOR LABORATORY TESTS

• Serum Tg and thyroglobulin antibodies should be measured every 6-12 months in patients post total or near total thyroidectomy with or without remnant ablation

• Rising Tgl evels are suspicious for growing thyroid tissue or cancer

• Periodic serum Tg and neck US should be done in patients who have had a less than total thyroidectomy, and those with total thyroidectomy but not RAI ablation

Long term follow up

RECOMMENDATIONS FOR CERVICAL US

• Following surgery, perform cervical US to evaluate thyroid bed and central and lateral cervical nodal compartments at 6-12 months and then periodically depending on recurrence risk and Tg status

• US suspicious nodes >5-8mm in smallest diameter should be biopsied for cytology with Tg measurement in needle washout fluid

• US suspicious nodes <5-8mm in largest diameter may be followed without biopsy with intervention if there is growth or if node threatens vital structures

Long term follow up

RECOMMENDATIONS FOR TSH

Persistent disease

•Maintain serum TSH<0.1mU/L indefinitely

•Clinically and biochemically disease free but presented with high risk

Maintain serum TSH 0.1-0.5mU/L for 5-10 years

Free of disease with low recurrence risk

•Maintain serum TSH in low normal range 0.3-2mU/L indefinitely

•Clinically free of disease who have not undergone remnant ablation with undetectable suppressed serum Tg and normal neck US

•Maintain serum TSH in low normal range 0.3-2mU/L

Long term follow up

RECOMMENDATIONS FOR SURGERY FOR METASTASIS

• Therapeutic comprehensive compartmental lateral and/or central neck dissection sparing uninvolved vital structures should be performed for persistent or recurrent disease confined to neck

• Limited compartmental lateral and/or central neck dissection should be performed for recurrent disease within compartments that have had prior comprehensive dissection and/or external beam radiotherapy

• Surgery for aerodigestive invasive disease is recommended in combination with RAI and/or external beam radiotherapy

Radio therapy in Metastasis

RADIOTHERAPY INDICATIONS

•Unresectable gross residual or recurrent cervical disease

• Painful bone metastases

• Metastases in critical locations unamenable to surgery likely to result in significant complications